BioCentury | Jan 6, 2017

Tiers of disappointment

A bad year for biotech was closed with an even worse 4Q16 as volatility ahead of the U.S. elections and continued concerns around drug pricing held every market cap band in the red despite a...
BioCentury | Dec 14, 2016
Clinical News

Actimmune: Ph III STEADFAST data

Horizon discontinued development of Actimmune to treat Friedreich's ataxia after top-line data from the double-blind, U.S. Phase III STEADFAST trial in 92 patients showed that thrice-weekly subcutaneous Actimmune missed the primary endpoint of improving FARS-mNeuro...
BioCentury | Dec 9, 2016
Clinical News

Horizon dips on Phase III Friedreich's ataxia miss

Horizon Pharma plc (NASDAQ:HZNP) dropped $4.36 (22%) to $15.03 on Thursday after it said Actimmune interferon (IFN) gamma-1b missed the primary endpoint in the Phase III STEADFAST trial to treat Friedreich's ataxia. The company said...
BioCentury | Jul 11, 2016

Rethinking risk

Steve Edelson, Senior Editor The second half does not contain the high-impact, sector-moving milestones seen in the first six months of the year, but investors still have at least 90 late-stage milestones from which to...
BioCentury | May 30, 2016
Company News

Boehringer Ingelheim, Horizon Pharma deal

Boehringer Ingelheim granted Horizon exclusive rights to develop and commercialize interferon (IFN) gamma-1b outside of the U.S., Canada and Japan, where Horizon already holds rights. Boehringer will receive EUR25 million ($28 million) up front. Horizon...
BioCentury | May 16, 2016
Clinical News

Actimmune interferon gamma-1b: Completed Phase III enrollment

Horizon completed enrollment of 90 patients in the double-blind, placebo-controlled, U.S. Phase III STEADFAST trial evaluating subcutaneous Actimmune thrice weekly for 26 weeks. Patients will receive an initial dose of 10 ug/m 2 Actimmune, which...
BioCentury | May 7, 2016
Financial News

ACT Genomics raises $12.5M series B

Diagnostics developer ACT Genomics Co. Ltd. (Taipei City, Taiwan) raised $12.5 million in a series B round led by Hotung Group and CDIB Capital Management. Existing investors including the Eminent II fund of TaiAn Technologies,...
BioCentury | Jan 11, 2016

Sowing season

Stephen Hansen, Associate Editor BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year. This...
BioCentury | Jan 4, 2016
Clinical News

Actimmune interferon gamma-1b: Phase I started

Horizon began an open-label, U.S. Phase I trial to evaluate subcutaneous Actimmune every other day in combination with IV Opdivo nivolumab in patients with advanced solid tumors who have progressed on >=1 prior systemic therapy....
BioCentury | Sep 14, 2015
Company News

Fox Chase Cancer Center, Horizon Pharma deal

Horizon and Fox Chase partnered to study Horizon’s Actimmune with PD-1 / PD-L1 inhibitors in cancer, including advanced urothelial and renal cell carcinoma. The first study, which is expected to begin later this year, will...
Items per page:
1 - 10 of 245